SK Capital Partners Acquires Majority Stake in SEQENS

December 16, 2021

Funds advised by SK Capital Partners acquired a majority shareholding in SEQENS, investing alongside Bpifrance, Nov Santé, Mérieux Equity Partners, Ardian, Eximium and SEQENS' management. The deal includes the integration of Wavelength Pharmaceuticals into SEQENS and the prior divestiture of certain non-core mineral specialties assets; SEQENS emerges as a strengthened pharmaceutical CDMO with ~€1.1bn revenue and ~3,200 employees.

Buyers
SK Capital Partners, Bpifrance, Nov Santé, Mérieux Equity Partners, Ardian, Eximium, SEQENS management team
Targets
SEQENS
Sellers
Eurazeo
Industry
Pharmaceuticals
Location
Auvergne-Rhône-Alpes, France
Transaction Type
Buyout

Explore More

Related articles

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.

Find buyers like these →